IND Safety Analysis Requires Broader Unblinding Of Reports, FDA Advises
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors should create safety assessment committees, draft guidance recommends.
You may also be interested in...
US FDA Is No Longer ‘Getting Crap’ From Sponsors In IND Safety Reports, Temple Says
FDA’s Robert Temple says he is gratified by the way companies have implemented the agency’s guidance on IND safety reporting. Merck, AbbVie and Janssen representatives discuss issues with unblinding data and the value of an aggregate analysis at DIA’s annual meeting.
IND Safety Reporting: Stakeholders Tussle Over Which Adverse Events To Report, Proper Oversight Body
US FDA officials, drug sponsors discussing creation of library of adverse event rates.
US Supreme Court Preview: ‘Skinny’ Labels, FTC, And FCA – But No Tecfidera As Biogen Loses Bid
Teva’s carve-out fight with GSK over generic Coreg will see the Solicitor General weigh in. Amgen and Juno’s patent petitions remain pending, and the high court stays a Federal Circuit decision invalidating Novartis’ Gilenya patent.